Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 1 - 8 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC1004 | Angiotensin I (human, mouse, rat) |
|
Endogenous peptide substrate for angiotensin converting enzyme (ACE); precursor to the vasoconstrictor peptide angiotensin II.
|
|
| BCC1008 | Endomorphin-1 |
|
Endogenous peptide with an exceptionally high affinity (K<sub>i</sub> = 360 pM) and selectivity for <span class='symbol'>μ</span> opioid receptors (4000- and 15000-fold preference over <span class='symbol'>δ</span> and <span class='symbol'>κ</span> respectively).
|
|
| BCC1016 | LEP (116-130) (mouse) |
|
Synthetic leptin peptide fragment. Restricts weight gain and reduces food intake in female mice lacking endogenously circulating active leptin.
|
|
| BCC1026 | Amyloid β-Peptide (10-20) (human) |
|
Soluble amyloid β-peptide fragment that is a substrate for gelatinase A/type IV collagenase/MMP-2 and APP secretase; cleaved between Lys16 and Leu17.
|
|
| BCC1027 | Amyloid Beta-peptide (25-35) (human) |
|
Fragment of human amyloid <span class='symbol'>β</span>-peptide, functionally required for the neurotrophic and neurotoxic effects associated with Alzheimer's disease.
|
|
| BCC1028 | Myelin Basic Protein (87-99) |
|
Encephalitogenic peptide that induces T cell proliferation with Th1 polarization in the CNS. Major antigenic component implicated in the pathophysiology of multiple sclerosis.
|
|
| BCC1029 | Angiotensin (1-7) |
|
Endogenous peptide fragment. Induces vasorelaxation through release of NO and prostaglandins, perhaps through activation of a non-AT1, non-AT2 receptor, Mas. Counteracts the vasoconstrictive and proliferative effects of angiotensin II and stimulates vasopressin (anti-diuretic hormone) release in vivo.
|
|
| BCC1031 | Angiotensin III (human, mouse) |
|
Endogenous vasoconstrictor peptide, formed from the conversion of angiotensin II in vivo. Acts at both AT1 and AT2 receptors and increases vasopressin (anti-diuretic hormone) release and blood pressure.
|
|